Intestinal Research

Original Article

A Double-Blind, Randomized, Active Drug Comparative, Parallel-Group, Multi-Center Clinical Study to Evaluate the Safety and Efficacy of Probiotics (Bacillus licheniformis, Zhengchangsheng® capsule) in Patients with Diarrhea: Jun Heo, Sung Kook Kim, Kyung Sik Park, Hye Kyung Jung, Joong Goo Kwon, Byung Ik Jang; Intest Res 2014;12(3):236-244. Published online July 25, 2014; DOI: https://doi.org/10.5217/ir.2014.12.3.236

<b>Background/Aims</b><br/>

Bacillus Licheniformis, a probiotic used in the treatment of diarrhea, has been shown to suppress the growth of pathologic bacteria. This study was performed to assess the therapeutic efficacy and safety of Zhengchangsheng® (Bacillus Licheniformis) in comparison with another probiotic, Bioflor® (Saccharomyces Boulardii) for the treatment of diarrhea.

Methods

Patients with diarrhea (n=158) were randomized to receive Zhengchangsheng® or Bioflor® for 5 days. The existence or non-existence of formed feces, changes in daily stool frequency, improvement of subjective symptoms, and changes in the severity of diarrhea were compared.

Results

Of the 158 full analysis set (FAS) patient population, 151 patients comprised the per protocol (PP) analysis. The rates of recovered to formed feces in the Bacillus and Saccharomyces groups were 91.0% vs. 95.0% in the FAS (P=0.326) and 90.5% vs. 96.1% in the PP analysis (P=0.169), respectively. The mean duration of diarrhea changing to formed feces was 3.15±1.10 days in the Bacillus group and 3.22±1.01 in the Saccharomyces group (P=0.695, FAS). The frequency of defecation, subjective symptoms, and degree of severe diarrhea were improved in both groups, however, there were no statistically significant differences between the 2 groups. Analysis of the 95% confidence intervals for the differences in the rate of recovery to formed feces between the 2 groups met the criteria for non-inferiority of Bacillus compared to Saccharomyces. No significant adverse events were observed during the study period.

Conclusions

Zhengchangsheng® is not inferior to Bioflor® in therapeutic efficacy and is a safe and useful therapeutic agent for the treatment of diarrhea.

Citations

Citations to this article as recorded by

Prophylactic administration of overproducing-abscisic acid Bacillus licheniformis attenuated DSS-induced colitis in mice by regulating the gut microbiota and immune activity
Zeyan Xu, Lijiang Zhao, Mengting Wu, Anqi Cui, Wei Chen, Guohao Zheng, Jingyi Zhou, Daqing Gao, Ruihua Shi
BMC Microbiology.2025;[Epub] CrossRef
Common protein networks for various drug regimens of major depression are associated with complement and immunity
Seungyeon Lee, Sora Mun, Jiyeong Lee, Hee-Gyoo Kang
Journal of Psychopharmacology.2024; 38(9): 798. CrossRef
Baseline gut microbiome impacts probiotics Bacillus licheniformis CMCC63516 in modulating the gut microbiome and preventing antibiotic‐associated diarrhea: A double‐blind, randomized controlled trial
Qian Zhou, Wenkui Dai, Yanmin Bao, Jing Chen, Xiaohua Han, Changshan Liu, Meijie Hou, Huisheng Yao, Changsuo Hao, Shuaicheng Li, Yuejie Zheng
Clinical and Translational Medicine.2023;[Epub] CrossRef
Weizmannia coagulans: an Ideal Probiotic for Gut Health
Shiqi Zhang, Pinglan Li, Suwon Lee, Yu Wang, Chunming Tan, Nan Shang
Food Science and Human Wellness.2023; : 1. CrossRef
Bacillus licheniformis prevents and reduces anxiety-like and depression-like behaviours
Siyuan Feng, Chen Meng, Yiyuan Liu, Yue Yi, Axin Liang, Yingyu Zhang, Zikai Hao
Applied Microbiology and Biotechnology.2023; 107(13): 4355. CrossRef
Bacteremia caused by accidental injection of Bacillus licheniformis microbiota modulator through the central venous catheter
Chuan Zhong, Fen Wang, Haining Zhou, Jiarui Liu, Jiewei Hu, Yongjun Chen
Medicine.2022; 101(4): e28719. CrossRef
Bacillus licheniformis Reshapes the Gut Microbiota to Alleviate the Subhealth
Siyuan Feng, Chen Meng, Zikai Hao, Hong Liu
Nutrients.2022; 14(8): 1642. CrossRef
The effect of multispecies probiotics on cognitive reactivity to sad mood in patients with Crohn’s disease
Lipei Wu, Fujun Shen, Weiwei Wang, Chunrun Qi, Chunbin Wang, Anquan Shang, Shihai Xuan
Journal of Functional Foods.2021; 82: 104431. CrossRef
Bacillus licheniformis Zhengchangsheng® Inhibits Obesity by Regulating the AMP-Activated Protein Kinase Signaling Pathway
Xiaojie Lu, Yue Jing, Xiaofei Zhou, Naisheng Zhang, Jiandong Tai, Yongguo Cao
Probiotics and Antimicrobial Proteins.2021; 13(6): 1658. CrossRef
Oral Supplements of Combined Bacillus licheniformis Zhengchangsheng® and Xylooligosaccharides Improve High‐Fat Diet‐Induced Obesity and Modulate the Gut Microbiota in Rats
Yuyuan Li, Man Liu, He Liu, Xiaoqing Wei, Xianying Su, Ming Li, Jieli Yuan, Zongbao K. Zhao
BioMed Research International.2020;[Epub] CrossRef
Bacillus licheniformis Zhengchangsheng® attenuates DSS-induced colitis and modulates the gut microbiota in mice
Y. Li, M. Liu, J. Zhou, B. Hou, X. Su, Z. Liu, J. Yuan, M. Li
Beneficial Microbes.2019; 10(5): 543. CrossRef
Broad Prebiotic Potential of Non-starch Polysaccharides from Oats (Avena sativa L.): an in vitro Study
VANDA SARGAUTIENE, ILVA NAKURTE, VIZMA NIKOLAJEVA
Polish Journal of Microbiology.2018; 67(3): 307. CrossRef
Effect of Bacillus subtilis C-3102 on loose stools in healthy volunteers
M. Hatanaka, K. Yamamoto, N. Suzuki, S. Iio, T. Takara, H. Morita, T. Takimoto, T. Nakamura
Beneficial Microbes.2018; 9(3): 357. CrossRef
Rapid and simple detection of endospore counts in probiotic Bacillus cultures using dipicolinic acid (DPA) as a marker
Xiao-Sheng Liang, Chun Liu, Zhu Long, Xiao-Hua Guo
AMB Express.2018;[Epub] CrossRef
Gut Microbiota in Health and Probiotics in Functional Bowel Disease
Jai Hyun Rhyou
The Ewha Medical Journal.2017; 40(1): 22. CrossRef
Separation and determination of peptide metabolite of Bacillus licheniformis in a microbial fuel cell by high-speed capillary micellar electrokinetic chromatography
Wei Wang, Ruiguang Bai, Xiaoyu Cai, Ping Lin, Lihong Ma
Journal of Separation Science.2017; 40(22): 4446. CrossRef
Evaluation of chitosan hydrochloride-alginate as enteric micro-probiotic-carrier with dual protective barriers
Qing-Xi Wu, Xin Xu, Qiu Xie, Wang-Yu Tong, Yan Chen
International Journal of Biological Macromolecules.2016; 93: 665. CrossRef

11,078 View
73 Download
18 Web of Science
17 Crossref

Case Reports

A Case of Mantle Cell Lymphoma Presenting as a Small Intestinal Stricture: Jae Bum Park, Joong Goo Kwon, Jae Young Oh, Ji-Min Han, Jin Tae Jung, Eun Young Kim, Ho Gak Kim, Hun Mo Ryoo, Hyun Dong Chae, Chang Ho Cho; Intest Res 2012;10(3):300-304. Published online July 31, 2012; DOI: https://doi.org/10.5217/ir.2012.10.3.300

Abstract PDF: Mantle cell lymphoma (MCL) is a subtype of B-cell non-Hodgkin's lymphoma (NHL), accounting for 3-10% of NHL. MCL involves the gastrointestinal (GI) tract in 10-30% of patients and common sites of MCL GI tract involvement are the colorectum and stomach, but any region of the GI tract may be involved. GI tract involvement by MCL usually presents in the form of multiple lymphomatous polyposis involving several segments of the GI tract. A few cases of MCL presenting with a GI tract stricture have been reported. Here, we present a rare case of a small intestinal stricture caused by MCL and review the literature of this disease. (Intest Res 2012;10: 0-304)

2,351 View
19 Download

A Case of Granular Cell Tumor of Cecum Misdiagnosed as Carcinoid Tumor: Kyu Hyun Cho, Jin Tae Jung, Jimin Han, Joong Goo Kwon, Eun Young Kim, Chang Ho Cho; Intest Res 2010;8(2):191-194. Published online December 30, 2010; DOI: https://doi.org/10.5217/ir.2010.8.2.191

Abstract PDF

Granular cell tumors (GCTs) are relatively rare submucosal tumors with an incidence of 10% in the gastrointestinal tract. In the gastrointestinal tract, the esophagus is the most common site for GCTs, while the colorectum is an uncommon site. GCTs are often found incidentally as small, submucosal tumors on esophagogastroduodenoscopy. On endoscopic ultrasonography (EUS), GCTs usually have a homogeneous hypoechoic pattern. EUS cannot adequately distinguish GCTs from carcinoid tumors. We report a case of a cecal GCT that was misdiagnosed as a carcinoid tumor by EUS and was treated by endoscopic mucosal resection, along with a review of the literature. (Intest Res 2010;8:191-194)

Citations

Citations to this article as recorded by

Granular Cell Tumors of the Cecum: Report of Two Cases and Review of Literature
Nam Yeol Cho, Yu-Ah Choi, Gye Sung Lee
Keimyung Medical Journal.2020; 39(2): 86. CrossRef

2,679 View
19 Download
1 Crossref

First
Prev
Page of 1
Next
Last

Search